Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease.
antiplatelet
atrial fibrillation
diabetes mellitus
discontinuation
non-persistence
peripheral arterial disease
reinitiation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
21 Sep 2021
21 Sep 2021
Historique:
received:
02
08
2021
revised:
09
09
2021
accepted:
16
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet therapy and how many of them discontinued therapy after reinitiation, and (b) to identify patient- and medication-related characteristics associated with the likelihood of reinitiation and discontinuation among reinitiators. The analysis of reinitiation was conducted on 3032 nonpersistent users of antiplatelet agents aged ≥65 years, with PAD newly diagnosed in 2012. Discontinuation (i.e., a treatment gap of ≥6 months without antiplatelet medication prescription) was analysed in 2006 reinitiating patients. To identify factors associated with the likelihood of reinitiation and discontinuation, Cox regression with time-dependent covariates was used. Reinitiation was recorded in 2006 (66.2%) of 3032 patients who had discontinued antiplatelet medication. Among these 2006 reinitiators, 1078 (53.7%) patients discontinued antiplatelet therapy again. Ischemic stroke and myocardial infarction during nonpersistence and bronchial asthma/chronic obstructive pulmonary disease were associated with an increased likelihood of reinitiation. University education was associated with discontinuation among reinitiators. Factors associated with the probability of reinitiation and discontinuation in reinitiators make it possible to identify older PAD patients in whom "stop-starting" behaviour may be expected.
Identifiants
pubmed: 34572469
pii: biomedicines9091280
doi: 10.3390/biomedicines9091280
pmc: PMC8465359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : VEGA 1/0024/21
Références
J Am Coll Cardiol. 2012 Oct 9;60(15):1333-9
pubmed: 22999716
Circulation. 2017 Mar 21;135(12):e726-e779
pubmed: 27840333
Am J Cardiol. 2018 Sep 1;122(5):768-774
pubmed: 30057227
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Front Pharmacol. 2021 May 19;12:687549
pubmed: 34093210
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10):
pubmed: 29021332
PLoS One. 2019 Nov 15;14(11):e0225390
pubmed: 31730627
J Am Coll Cardiol. 2018 Nov 27;72(21):2675-2677
pubmed: 30466527
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
Heart. 2021 May 13;:
pubmed: 33985986
Cleve Clin J Med. 2006 Oct;73 Suppl 4:S2-7
pubmed: 17385385
Circulation. 1985 Oct;72(4):768-73
pubmed: 4028377
Vasa. 2018 Feb;47(2):99-108
pubmed: 29160765
BMJ. 2016 Jun 28;353:i3305
pubmed: 27353261
Expert Opin Pharmacother. 2020 Sep;21(13):1603-1616
pubmed: 32558590
Tech Vasc Interv Radiol. 2016 Jun;19(2):91-5
pubmed: 27423989
J Epidemiol Community Health. 2007 Dec;61(12):1091-7
pubmed: 18000133
Atherosclerosis. 2018 Aug;275:379-381
pubmed: 29843915
Acta Diabetol. 2015 Jun;52(3):547-56
pubmed: 25524433
Arch Intern Med. 2007 Apr 23;167(8):847-52
pubmed: 17452550
PLoS One. 2021 Apr 21;16(4):e0250289
pubmed: 33882106
Ann Intern Med. 2018 Jul 3;169(1):30-35
pubmed: 29946690
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Angiology. 2016 Oct;67(9):860-9
pubmed: 26764367
Eur J Vasc Endovasc Surg. 2019 Mar;57(3):442-450
pubmed: 30393062